Optimi Health to present at H.C. Wainwright 2026

Optimi Health Corp. (OPTH), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, reported that it will participate in the H.C.

Rhea-AI Filing Summary

Optimi Health Corp. (OPTH), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, reported that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference in New York, held September 14-16, 2026. A company presentation will be available on demand starting September 11, 2026, at 7:00 a.m. ET, and management plans to be available for one-on-one meetings throughout the conference. Optimi manufactures and distributes GMP-grade MDMA and botanical psilocybin drug products from its facilities in British Columbia, supplying active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally.

Key Figures

Conference dates: September 14-16, 2026 Presentation availability time: 7:00 a.m. ET Presentation availability date: September 11, 2026 +1 more

4 metrics

Conference dates September 14-16, 2026 H.C. Wainwright 28th Annual Global Investment Conference

Presentation availability time 7:00 a.m. ET On-demand company presentation available starting September 11, 2026

Presentation availability date September 11, 2026 Start date for on-demand Optimi Health presentation

Investor relations phone (778) 761-4551 Investor contact number for Optimi Health Corp.

Key Terms

GMP-grade, psychedelic drug products, Authorized Prescriber Scheme, Special Access Program, +1 more

5 terms

GMP-grade technical

"focused on manufacturing and distributing GMP-grade psychedelic drug products"

GMP-grade means a drug substance, ingredient or product was manufactured under Good Manufacturing Practice standards — a set of rules and documented controls that ensure consistent cleanliness, quality and traceability. For investors, GMP-grade items matter because they lower regulatory and safety risk, make products eligible for approval and sale in regulated markets, and reduce the chance of costly recalls or supply disruptions; think of it like food prepared in a certified commercial kitchen rather than a home stove.

psychedelic drug products medical

"commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products"

Authorized Prescriber Scheme regulatory

"prescribed to patients in Australia under the country’s Authorized Prescriber Scheme"

An authorized prescriber scheme lets a qualified clinician or group of clinicians prescribe a specific medicine to eligible patients without obtaining individual approvals each time, under rules set by health regulators. For investors, it matters because the scheme can speed access to medicines and broaden sales once clinicians are approved, similar to giving a trusted shopkeeper a standing license to sell a product rather than requiring a new permit for every sale.

Special Access Program regulatory

"accessible in Canada through the Special Access Program"

A special access program is a regulated pathway that lets patients use an experimental drug, vaccine, or medical device outside clinical trials when no approved options are available. Think of it like allowing a small number of people to try a prototype product before wide release; for investors it can create early, limited revenue, generate real‑world safety and use data, and carry regulatory and reputational risks that can affect a company’s valuation.

GMP-compliant facilities technical

"at its GMP-compliant facilities in British Columbia, Canada"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Optimi Health Corp. (OPTH) announce in this Form 6-K?

Optimi Health Corp. announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference in New York, with an on-demand presentation and availability for one-on-one investor meetings during the event.

When and where will OPTH participate in the H.C. Wainwright conference?

Optimi will participate in the H.C. Wainwright 28th Annual Global Investment Conference on September 14-16, 2026, at the Lotte New York Palace Hotel in New York.

When will Optimi Health’s OPTH conference presentation be available?

The Optimi Health presentation will be available on demand starting Friday, September 11, 2026, at 7:00 a.m. ET, via an online link referenced in the announcement.

How can investors arrange one-on-one meetings with Optimi Health at the conference?

Investors can schedule one-on-one meetings with Optimi management by contacting their H.C. Wainwright representative, emailing meetings@hcwco.com, or registering for the conference through the link referenced in the announcement.

What is the business focus of Optimi Health Corp. (OPTH)?

Optimi Health is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products, including validated MDMA and botanical psilocybin, for regulated mental health therapies.

In which countries are Optimi Health’s psychedelic products currently accessible?

Optimi states its products are prescribed to patients in Australia under the Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.

How can investors contact Optimi Health Corp. (OPTH) investor relations?

Investors can contact Optimi via phone at (778) 761-4551, email investors@optimihealth.ca, or through investor relations contact CORE at ir@optimi.net.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 08:30 AM Accepted by SEC EDGAR 09/08/2026 - 08:30 AM Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2026

Commission File Number: 001-43304

Optimi Health Corp.
(Translation of registrant's name into English)

269 David Brown Way
Princeton, B.C. V0X 1W0
Canada
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

EXHIBIT INDEX

Exhibit		Description of Exhibit
99.1		Press Release

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Optimi Health Corp.
		(Registrant)
Date: September 8, 2026		/s/ Dane Stevens
		Dane Stevens
		Chief Executive Officer, Chief Marketing Officer and Director

EXHIBIT 99.1

 

Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (Nasdaq: OPTH) (CSE: OPTI) (“Optimi” or the “Company”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced that it will participate in the H.C. Wainwright 28^th Annual Global Investment Conference. The conference will be held September 14-16, 2026, at the Lotte New York Palace Hotel.

A Company presentation will be available on demand here beginning Friday, September 11, 2026, at 7:00 a.m. ET. Management will be available for one-on-one meetings throughout the conference.

Investors interested in scheduling a meeting with Optimi management should contact their H.C. Wainwright representative, email meetings@hcwco.com, or register for the conference here.

About Optimi Health Corp.

Optimi Health Corp. is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country’s Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.

For more information, please visit optimi.net.

For more information, please contact:

Dane Stevens, CEO
Optimi Health Corp.
(778) 761-4551
investors@optimihealth.ca
www.optimihealth.ca

Investor Relations Contact:

CORE IR
ir@optimi.net

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 2.9 KB